Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early detection of biologic treatment effectiveness in severe asthma using daily pulmonary biomarker fluctuation analysis
NL-OMON56494Recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Jan 2025
- Countries
- 1
01
Overview
Open-label, single-arm trial in severe asthma, sponsored by Amsterdam University Medical Center. Primary endpoints: Fluctuation patterns of Respicorder pulmonary biomarkers, Association between fluctuation patterns and later biologic treatment success and 2 more. Started Jan 2025; status: recruiting.
02
Conditions
severe asthma
Beyond the preview
Go deeper on NL-OMON56494.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56494.